Trospium chloride treatment of overactive bladder

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 283-295

  Biastre, Kelly ^a   Burnakis, Thomas ^b  

^a BAPTIST MEDICAL CENTER   (United States)

^b Baptist Medical Center   (United States)

Author keywords

Overactive bladder; Trospium; Urgency; Urinary incontinence

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DARIFENACIN; DIGOXIN; ESTERASE; METFORMIN; MORPHINE; MUSCARINIC RECEPTOR; OXYBUTYNIN; PANCURONIUM; PLACEBO; PROCAINAMIDE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; VANCOMYCIN;

ABDOMINAL PAIN; ADJUSTMENT; APPLICATION SITE PRURITUS; BLINDNESS; BLOOD BRAIN BARRIER; BLURRED VISION; CENTRAL NERVOUS SYSTEM; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL STUDY; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CREATININE CLEARANCE; DAYTIME SOMNOLENCE; DIZZINESS; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; ERYTHEMA; GROUPS BY AGE; HEADACHE; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE EXCRETION; LIPOPHILICITY; MICTURITION; NERVOUS SYSTEM; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PARENT; PLASMA PROTEIN BINDING; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; SYMPTOM; SYSTEMATIC REVIEW; TABLET; TRANSDERMAL PATCH; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINARY EXCRETION; URINARY FREQUENCY; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; URINE VOLUME; XEROSTOMIA;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; MUSCARINIC ANTAGONISTS; NORTROPANES; URINARY BLADDER, OVERACTIVE;

EID: 60349085888     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L160     Document Type: Review

References (76)

1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6.
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36.
3. Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: results from the noble program (abstract). Int Urogynecol J 2001;12(suppl):S66.
4. Abrams P, Kelleher CJ, Kerr L, Rogers R. Overactive bladder significantly affects quality of life. Am J Managed Care 2000;6(11 suppl):S580-90.
5. Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med 2006;119(suppl 3A):29S-36S.
6. Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123-8.
7. Chu FM, Dmochowski R, Pathophysiology of overactive bladder. Am J Med 2006;119(suppl):3S-8S.
8. Tyagi S, Thomas CA, Hayashi Y, Chancellor MB. The overactive bladder: epidemiology and morbidity, Urol Clin North Am 2006;33:433-8.
9. Ouslander JG. Management of overactive bladder. N Engl J Med 2004;350:786-99.
10. Rosenburg M, Hazzard MA. Insights into the diagnosis and management of overactive bladder. Business Briefing: US Kidney & Urological Disease 2005:97-100.
11. Ko Y, Lin Swu-Jane, Salmon W, Bron MS. The impact of urinary incontinence on quality of life of the elderly. Am J Manag Care 2005;11(suppl):S103-11.
12. Lazzeri M, Spinelli M. The challenge of overactive bladder therapy: alternative to antimuscarinic agents. Int Braz J Urol 2006;32:620-30.
13. Haab F, Castro-Diaz D. Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 2005;59:931-7.
14. Washington-Cannon T, Chancellor MB. Pharmacotherapy of the overactive bladder and advances in drug delivery. Clin Obstet Gynecol 2002;45:205-17.
15. Scottish Intercollegiate Guidelines Network (SIGN). Management of urinary incontinence in primary care. A national clinical guideline. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network (SIGN); 2004 Dec., 41p. (SIGN publication no. 79).
16. Diefenbach K, Donath F, Maurer A, et al. Randomized, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride, and placebo on sleep in healthy young volunteers. Clin Drug Invest 2003;23:395-404.
17. MacDiarmid SA. Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached? BJU Int 2007;99:8-12.
18. Abrams P, Anderson Karl-Erik. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006.
19. Cardozo L. The overactive bladder syndrome: treating patients on an individual basis. BJU Int 2007;99:1-7.
20. Prescribing information. Sanctura (trospium chloride). Lexington, MA, and East Hanover, NJ: Odyssey Pharmaceutical Inc. and Indevus Pharmaceuticals Inc., 2004. www.sanctura.com (accessed 2007 Oct 15).
21. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Multicenter phase III trial studying trospium chloride in patients with overactive bladder. Urology 2006;67:275-80.
22. Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S; Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311-5.
23. Prescribing information. Sanctura XR (trospium chloride extended-release). Lexington, MA, and East Hanover, NJ: Odyssey Pharmaceutical Inc., and Indevus Pharmaceuticals Inc., 2004. www.sancturaxr.com (accessed 2008 Jun 5).
24. Staskin D, Sand P, Zinner N, Dmochowski R, for the Trospium Study Group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol 2007;178:978-84.
25. Torodova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-44.
26. Dmochowski R, Sand P, Zinner N, Staskin D. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. J Urol 2008;71:449-54.
27. Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol 1999;161:1809-12.
28. Davila GW, Daugherty CA, Sanders SW, Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-5.
29. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001;76:358-63.
30. Dionkno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-95.
31. Prescribing information. Ditropan XL (oxybutynin chloride extended-release). 2004. www.ditropanxl.com/active/janus/en-US/assets/common/ company/pi/ditropanxl.pdf (accessed 2007 Oct 15).
32. Dmochowski RR, Nitti V, Staskin D, Luber K, Appell R, Davila GW. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005;23:263-70.
33. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double blind placebo and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-10.
34. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002;50:799-807.
35. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
36. Prescribing information. Detrol LA (long-acting tolterodine tartrate), 2005. http://pfizer.com/pfizer/download/uspi-detrol-la.pdfhttp://pfizer.com/ pfizer/download/uspi-detrol-la.pdf (accessed 2007 Oct 15).
37. Foote J, Glavind K, Kradlidis G, Wyndaele JJ. Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005;48:471-7.
38. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability, and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001.
39. Prescribing information. Enablex (darifenacin), 2006. www.pharma.us.novartis.com/product/pi/pdf/enablex.pdf (accessed 2007 Oct 15).
40. Napier C, Gupta P. Darifenacin is selective for the human recombinant M3 receptor subtype (abstract 445). Presented at: 32nd Annual Meeting of the International Continence Society, Heidelberg, Germany, August 28-30, 2002.
41. Steers WD. Darifenacin: pharmacology and clinical usage. Urol Clin North Am 2006;33:475-82.
42. Prescribing information. VESIcare (solifenacin succinate), 2004. www.vesicare.com/assets/vesicare-prescribing-info.pdf (accessed 2007 Oct 15).
43. Metello J, Nogueira B, Torgal M, et al. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride. Int Urogynecol J 2007;18:1021-5.
44. Kreder K. Solifenacin. Urol Clin North Am 2006;33:483-90.
45. Staskin DR, MacDiarmid SA. Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med 2006;119(suppl 3A):24S-8S.
46. National Institute for Health and Clinical Excellence. Urinary incontinence. www.nice.org.uk/CG040 (accessed 2008 Jan 11).
47. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006;26:1694-702.
48. Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002.
49. Hester SA. New dosage form: Sanctura XR (trospium extended-release) Pharmacist's Letter/Prescriber's Letter 1, 2008;24:240108.
50. Epstein B, Gums J, Molina E. Newer agents for the management of overactive bladder. Am Fam Physician 2006;74:2061-8.
51. Doroshyenko O, Jetter A, Odenthal KP, et al. Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005;44:701-20.
52. Singh-Franco D, Machado C, Tuteja S, Zapantis A. Trospium chloride for the treatment of overactive bladder with urge incontinence. Clin Ther 2005;27:511-30.
53. Staskin D. Trospium chloride: distinct among other anticholinergic agents available for the treatment of overactive bladder. Urol Clin North Am 2006;33:465-73.
54. Pietzsko A, Dimpfel W, Schwantes U, et al. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994;47:337-43.
55. Torodova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-44.
56. Kim Y, Yoshimura N, Masuda H, DeMiguel F, Chancellor MB. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder afferent pathways. Urology 2005;65:238-42.
57. Rudy D, Cline K, Harris R, Goldberg K, Dmochowski R. Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment. BJU Int 2006;97:540-6.
58. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol 1999;85:299-304.
59. Guay DRP. Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence. Ther Clin Risk Manage 2005;1:157-66.
60. Chancellor MB, de Miguel F. Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential. Geriatrics 2007;62:15-24.
61. Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005;8:604-7.
62. Dmochowski RR. Overactive bladder pharmacotherapy: what does the future hold? BJU Int 2007;99:13-6.
63. Alloussi S, Laval K, Eckert R, et al. Trospium chloride (Spasmo-lyt) in patients with motor urge syndrome (detrusor instability): a double-blind, randomized, multi-center, placebo-controlled study. J Clin Res 1998;1:439-51.
64. Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int 2000;85:659-64.
65. Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging 2005;22:1013-28.
66. Stohrer M, Bauer P, Giannetti BM, et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries, a multi-center, placebo-controlled, double blind trial. Urol Int 1991;47:138-43.
67. Madersbacher H, Stohrer M, Richter R, et al. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. BJU Int 1995;75:452-6.
68. Osca-Garcia JM, Martinez AE, Conejero SJ, Jiminez Cruz JF. Trospium chloride versus oxybutynin in the treatment of bladder neurological disorders: a double-blind, randomized clinical trial (abstract). BJU Int 1997;80:44.
69. Junemann KP, Al-Shukri S. Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome; a double-blind, placebo-controlled, multi-center clinical trial (abstract 107 85B). Neurourol Urodyn 2000;19:488-90.
70. Hofner K, Halaska M, Ralph G, et al. Tolerability and efficacy of trospium chloride in a long term treatment (52 weeks) in patients with urgesyndrome: a double-blind, controlled, multicenter clinical trial (abstract). International Continence Society, Finland. Neurourol Urodyn 2000;19:487-8.
71. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20:392-9.
72. Lopez Pereira P, Miguelez C, Caffarati J, Estornell F, Anguera A. Trospium chloride for the treatment of detrusor instability in children. J Urol 2003;170:1978-81.
73. Andersson KE, Yoshida M. Antimuscarinics and the overactive detrusor: which is the main mechanism of action? Eur Urol 2003;43:1-5.
74. Hay-Smith J, Hervison P, Ellis G, Moore K. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2002;3:CD00378.
75. Kroenke K, Pinholt EM. Reducing polypharmacy in the elderly. A controlled trial of physician feedback. J Am Geriatr Soc 1990;38:31-6.
76. Sandage B, Sabounjian L, Shipley J, et al. Predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin. J Clin Pharmacol 2006;46:776-84.